Jupiter Asset Management Ltd. Sells 858,296 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Jupiter Asset Management Ltd. decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 41.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,197,619 shares of the biotechnology company’s stock after selling 858,296 shares during the period. Jupiter Asset Management Ltd. owned approximately 0.57% of BioCryst Pharmaceuticals worth $9,341,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Larson Financial Group LLC lifted its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals in the third quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $81,000. 85.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citizens Jmp raised their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $20.70.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.10% of the stock is currently owned by insiders.

BioCryst Pharmaceuticals Stock Down 2.1%

Shares of NASDAQ:BCRX opened at $8.91 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The stock’s 50 day moving average is $9.16 and its 200-day moving average is $8.01. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -5.01 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period in the previous year, the business posted $0.20 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.